Phaseline

Targets › DHODH

DHODH (Dihydroorotate dehydrogenase): drug programs, companies and trials

7 programs from 7 companies in 13 trials: 5 Phase 2, 5 Phase 1, 3 Phase 3; Neurology, Oncology, Immunology; next expected readout Nov 2026.

Catalyzes the conversion of dihydroorotate to orotate with a quinone as electron acceptor, likely ubiquinone-10. Required for UMP biosynthesis via de novo pathway. (UniProt, Q02127)

Open in Phaseline: the race on DHODH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ImmunicVidofludimus (IMU-838)
Dihydroorotate dehydrogenase inhibitor
DHODHPhase 3Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Relapsing-Remitting Multiple Sclerosis (RRMS)Nov 2026
University Hospital, MontpellierTeriflunomide
Dihydroorotate dehydrogenase inhibitor
DHODHPhase 3Relapsing-Remitting Multiple Sclerosis (RRMS)Jun 2031
City of Hope Medical CenterLeflunomide
Dihydroorotate dehydrogenase inhibitor
DHODHPhase 2Smoldering Plasma Cell Myeloma; Recurrent Plasma Cell Myeloma; Advanced Pancreatic Adenocarcinoma; Acute Graft Versus Host Disease …Nov 2026
Kiora PharmaceuticalsKIO-104
Dihydroorotate dehydrogenase (DHODH) inhibitor
DHODHPhase 2Macular EdemaNov 2026
Peking University People's HospitalTeriflunomide
Dihydroorotate dehydrogenase inhibitor
DHODHPhase 2Immune Thrombocytopenia (ITP)Sep 2027
Jabez BioscienceJBZ-001
DHODH inhibitor
DHODHPhase 1Solid TumorFeb 2027
National Institute of Neurological Disorders and Stroke (NINDS)Teriflunomide
Dihydroorotate dehydrogenase inhibitor
DHODHPhase 1HAM/TSPDec 2027

Conditions

Relapsing-Remitting Multiple Sclerosis (RRMS) (2) Smoldering Plasma Cell Myeloma (1) Recurrent Plasma Cell Myeloma (1) Advanced Pancreatic Adenocarcinoma (1) Acute Graft Versus Host Disease (1) Chronic Graft Versus Host Disease (1) Immune Thrombocytopenia (ITP) (1) Multiple Sclerosis, Relapsing-Remitting (1) Multiple Sclerosis (1) HAM/TSP (1) Solid Tumor (1) Macular Edema (1)

Modalities

small molecule (6), mixed (1)

Companies

City of Hope Medical Center (1) Peking University People's Hospital (1) Immunic (1) National Institute of Neurological Disorders and Stroke (NINDS) (1) University Hospital, Montpellier (1) Jabez Bioscience (1) Kiora Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.